Patient demographics and clinical characteristics
| Characteristics | n (%) |
|---|---|
| Age (years) | 49.9 (28–75) |
| <50 | 97 (51.3) |
| ≥50 | 92 (48.7) |
| Operation type | |
| Breast-conserving surgery | 68 (36) |
| Mastectomy | 121 (64) |
| Axillary evaluation | |
| SLNB | 133 (70.4) |
| SLNB, then AD | 40 (21.2) |
| AD | 16 (8.4) |
| Pathologic node stage | |
| N0 | 133 (70.3) |
| N1mic | 16 (8.5) |
| N1 | 32 (17) |
| N2 | 7 (3.7) |
| N3 | 1 (0.5) |
| T stage | |
| T1a | 19 (10.1) |
| T1b | 11 (5.8) |
| T1c | 64 (33.9) |
| T2 | 89 (47.1) |
| Unknown | 6 (3.1) |
| Histology | |
| IDC | 180 (95.2) |
| ILC | 9 (4.8) |
| Grade | |
| I | 25 (13.2) |
| II | 96 (50.8) |
| III | 68 (36) |
| Subtype | |
| HR positive and HER2 negative | 120 (63.5) |
| HR positive and HER2 positive | 23 (12.2) |
| HR negative and HER2 positive | 27 (14.3) |
| HR negative and HER2 negative | 19 (10) |
| Ki67 ≥30%+ | 78 (41.3) |
| LVI positive | 61 (32.3) |
AD, axillary dissection; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; LVI, lymphovascular invasion; SLNB, sentinel lymph node biopsy.